IOVANCE BIOTHERAPEUTICS, INC. Depreciation
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Depreciation of $5.70 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2023-08-08
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2023-06-30 was $2.90M, a 31.82% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2023-03-31 was $2.80M, a 55.56% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2022-12-31 was $2.80M, a 115.38% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for the quarter ending 2022-09-30 was $2.50M, a 150.00% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for fiscal 2022 was $9.30M, a 200.00% increase from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for fiscal 2021 was $3.10M, a 181.82% increase from fiscal 2020.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for fiscal 2020 was $1.10M, a 8.33% decline from fiscal 2019.
- IOVANCE BIOTHERAPEUTICS, INC. depreciation for fiscal 2019 was $1.20M, a 20.00% increase from fiscal 2018.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2023-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.70M 10-Q · filed 2023-08-08 | $8.50M derived: sum of 3 quarters · filed 2023-08-08 | $11.00M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | $2.80M 10-Q · filed 2023-05-10 | $5.60M derived: sum of 2 quarters · filed 2023-05-10 | $8.10M derived: sum of 3 quarters · filed 2023-05-10 | $10.30M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.30M derived: sum of 2 quarters · filed 2023-02-28 | $7.50M derived: sum of 3 quarters · filed 2023-02-28 | $9.30M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $2.50M 10-Q · filed 2022-11-03 | $4.70M derived: sum of 2 quarters · filed 2022-11-03 | $6.50M 10-Q · filed 2022-11-03 | $7.80M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2022-06-30 | $2.20M 10-Q · filed 2022-08-04 | $4.00M 10-Q · filed 2023-08-08 | $5.30M derived: sum of 3 quarters · filed 2023-05-10 | $6.30M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-10 | $3.10M derived: sum of 2 quarters · filed 2023-05-10 | $4.10M derived: sum of 3 quarters · filed 2023-05-10 | $4.40M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.30M derived: sum of 2 quarters · filed 2023-02-28 | $2.60M derived: sum of 3 quarters · filed 2023-02-28 | $3.10M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.00M 10-Q · filed 2022-11-03 | $1.30M derived: sum of 2 quarters · filed 2022-11-03 | $1.80M 10-Q · filed 2022-11-03 | $2.00M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-04 | $700.00K 10-Q · filed 2022-08-04 | $1.00M derived: sum of 3 quarters · filed 2023-02-28 | $1.30M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $400.00K 10-Q · filed 2022-05-05 | $700.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.00M derived: sum of 3 quarters · filed 2023-02-28 | $1.20M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $600.00K derived: sum of 2 quarters · filed 2023-02-28 | $800.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.10M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-04 | $500.00K derived: sum of 2 quarters · filed 2021-11-04 | $800.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $200.00K 10-Q · filed 2021-08-05 | $500.00K 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $300.00K 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $1.20M 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | $1.00M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $1.00M 10-K · filed 2020-02-25 | ||||
| 2016-12-31 | $1.00M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $575.00K derived: sum of 2 quarters · filed 2018-03-12 | $1.00M 10-K · filed 2018-03-12 | $999.00K 10-K · filed 2016-03-11 | |
| 2015-09-30 | $266.00K 10-Q · filed 2015-11-06 | $691.00K 10-Q · filed 2015-11-06 | |||
| 2014-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $82.00K derived: sum of 2 quarters · filed 2017-03-09 | $100.00K 10-K · filed 2017-03-09 | $88.22K 10-K · filed 2015-03-16 | |
| 2014-09-30 | $5.00K 10-Q · filed 2015-11-06 | $23.00K 10-Q · filed 2015-11-06 | |||
| 2013-12-31 | $7.00K 10-K · filed 2016-03-11 | $7.09K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |